An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

References

• BalkauBEschwegeEThe diagnosis and classification of diabetes mellitus and impaired glucose regulationPickupJCWilliamsGTextbook of DiabetesOxfordBlackwell Science20032.12.13
   Google Scholar
• KarvonenMViik-KajanderMMoltchanovaELibmanILaPorteRTuomilehtoJFor the Diabetes mondiale (DiaMond). Incidence of Childhood Type 1 DiabetesWorldwideDiabetes Care2000231015161526
   PubMed Web of Science ®Google Scholar
• Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study GroupLancet2000355920787387610752702
   PubMed Web of Science ®Google Scholar
• KilpatrickESRigbyASAtkinsSLThe Diabetes Control and Complications Trial: the gift that keeps givingNat Rev Endocrinol2009510537545
   PubMed Web of Science ®Google Scholar
• SwinnenSGHoekstraJBDeVriesJHInsulin therapy for type 2 diabetesDiabetes Care200932Suppl 2S253S259
   PubMed Web of Science ®Google Scholar
• MeneghiniLFEarly insulin treatment in type 2 diabetes: what are the pros?Diabetes Care200932Suppl 2S270S274
   PubMedGoogle Scholar
• JehlePMMichelerCJehleDRBreitigDBoehmBOInadequate suspension of neutral protamine Hagedorn (NPH) insulin in pensLancet1999354919016041607
   PubMed Web of Science ®Google Scholar
• DeVriesJHNattrassMPieberTRRefining basal insulin therapy: what have we learned in the age of analogues?Diabetes Metab Res Rev2007236441454
   PubMed Web of Science ®Google Scholar
• PhilipsJCScheenAInsulin detemir in the treatment of type 1 and 2 diabetesVasc Health Risk Manage200623277283
   PubMedGoogle Scholar
• MarkussenJHavelundSKurtzhalsPAndersenASSoluble, fatty acid acylated insulins bind to albumin and show protracted action in pigsDiabetologia1996393281288
   PubMed Web of Science ®Google Scholar
• LindholmA2002New insulins in the treatment of diabetes mellitusBest Pract Res Clin Gastroenterol2009163475492
   PubMed Web of Science ®Google Scholar
• HermansenKMadsbadSPerrildHKristensenAAxelsenMComparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapyDiabetes Care2001242296301
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLRonnBBLower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesDiabetes200453616141620
   PubMed Web of Science ®Google Scholar
• DanneTLüpkeKWalteKVon SchuetzWGallMAInsulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetesDiabetes Care2003261130873092
   PubMed Web of Science ®Google Scholar
• HompeschMTroupinBHeiseTTime-action profile of insulin detemir and NPH insulin in patients with type 2diabetes from different ethnic groupsDiabetes Obes Metab200685568573
   PubMed Web of Science ®Google Scholar
• PlankJBodenlenzMSinnerFA double-blind, randomized, dose-response study investigating the pharmacodynamic and pharma-cokinetic properties of the long-acting insulin analog detemirDiabetes Care200528511071112
   PubMed Web of Science ®Google Scholar
• PorcellatiFRosettiPRicci BusciantellaNComparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetesDiabetes Care200730102447245217623819
   PubMed Web of Science ®Google Scholar
• KleinOLyngeJEndahlLDamholtBNosekLHeiseTAlbumin-bound basal insulin analogues (insulin detemir and NN344): comparable time – action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab200793290299
   PubMed Web of Science ®Google Scholar
• KingABOnce-dauly insulin detemir is comparable to once-dauly insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover studyDiabetes Obes Metab2009111697119120433
   PubMed Web of Science ®Google Scholar
• TschritterOSchäferSAKlettJInsulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulinDiabetes Obes Metab2009111110171026
   PubMed Web of Science ®Google Scholar
• TorloneEDiCianniGManninoDLapollaAInsulin analogs and pregnancy: an updateActa Diabetol2009463163172
   PubMed Web of Science ®Google Scholar
• SinghSRAhmadFLalAYuCBaiZBennettHEfficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysisCMAJ2009180438539719221352
   PubMed Web of Science ®Google Scholar
• PieberTRTreichelHCHompeschBComparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapyDiabet Med200724663564217381500
   PubMed Web of Science ®Google Scholar
• RobertsonKJSchoenleEGucevZMordhorstLGallMALudviqssonJInsulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetesDiabet Med20072412734
   PubMed Web of Science ®Google Scholar
• KleinOLyngeJEndahlLDamholtBNosekLHeiseTAlbumin-bound basal insulin analogues (insulin detemir and NN344): comparable time–action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab200793290299
   PubMed Web of Science ®Google Scholar
• Le FlochJPLévyMMosnier-PudarHAssessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT)Diabetes Care20093213237
   PubMed Web of Science ®Google Scholar
• HellerSKoenenCBodeBComparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trialClin Ther2009311020862097
   PubMed Web of Science ®Google Scholar
• BartleyPCBogoevMLarsenJPhilotheouALong-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trialDiabet Med200825444244918387078
   PubMed Web of Science ®Google Scholar
• DornhorstALüddekeHJHonkaMPREDICTIVE Study GroupSafety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE studyCurr Med Res Opin2008242369376
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2009321193203
   PubMed Web of Science ®Google Scholar
• HorvathKJeitlerKBergholdALong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20074182CD005613
   Google Scholar
• RayKKWildeMISivakumaranREffect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsLancet200937396771765177219465231
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology. Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic controlEndocr Pract2009156540559 Erratum in: Endocr Pract 2009;15(7):768–770.19858063
   PubMed Web of Science ®Google Scholar
• RaslovaKBogoevMRazILethGGallMAHâncuNInsulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetesDiabetes Res Clin Pract2004662193201 Corrigendum in: Diabetes Res Clin Pract 2006;72(1):112.
   PubMed Web of Science ®Google Scholar
• HaakTTiengoADraegerESuntumMWaldhäuslWLower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes Obes Metab200571566415642076
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDerezinskiTMartinez RavnGClausonPHomePA 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetes Care200629612691274
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasACharpentierGClausonPRavnGMRobertsVLThorsteinssonBComparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesClin Ther2006281015691581
   PubMed Web of Science ®Google Scholar
• LieblAPragerRBinzKKaiserMBergenstalRGallwitzBPREFER Study GroupComparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trialDiabetes Obes Metab20091114552
   PubMed Web of Science ®Google Scholar
• HollanderPCooperJBregnhøjJPedersenCBA 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClin Ther200830111976198719108786
   PubMed Web of Science ®Google Scholar
• RosenstockJDaviesMHomePDLarsenJKoenenCSchernthanerGA randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia2008513408416
   PubMed Web of Science ®Google Scholar
• RaskinPGylvinTWengWChaykinLComparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetesDiabetes Metab Res Rev2009256542548
   PubMed Web of Science ®Google Scholar
• SwinnenSGDainMPAronsonRA 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugsDiabetes Care201033 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• HolmanRRFarmerAJDaviesMJ4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetesN Engl J Med20093611817361747
   PubMed Web of Science ®Google Scholar
• DornhorstALüddekeHJHonkaMPREDICTIVE Study GroupSafety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE studyCurr Med Res Opin2008242369376
   PubMed Web of Science ®Google Scholar
• MeneghiniLFDornhorstASreenanSPREDICTIVE Study GroupOnce-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE studyCurr Med Res Opin20092541029103519281426
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• PurnellJQHokansonJEMarcovinaSMSteffesMWClearyPABrunzellJDEffect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications TrialJAMA199828021401469669786
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHRyysyLKauppilaMEffect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitusJ Clin Endocrinol Metab1997821240374043
   PubMed Web of Science ®Google Scholar
• PieberTRDraegerEKristensenAGrillVComparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs morning plus bedtime NPH insulinDiabet Med20052278508577
   PubMed Web of Science ®Google Scholar
• De LeeuwIVaguePSelamJLInsulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulinDiabetes Obes Metab200571738215642078
   PubMed Web of Science ®Google Scholar
• HermansenKFontainePKukoljaKKPeterkovaVLethGGallMAInsulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetesDiabetologia200447462262915298338
   PubMed Web of Science ®Google Scholar
• HomePBartleyPRussell-JonesDStudy to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trialDiabetes Care200427510811087
   PubMed Web of Science ®Google Scholar
• Russell-JonesDSimpsonRHyllebergBDraegerEBolinderJEffects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimenClin Ther2004265724736
   PubMed Web of Science ®Google Scholar
• StandlELangHRobertsAThe 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetesDiabetes Technol Ther20046557958815628811
   PubMedGoogle Scholar
• VaguePSelamJLSkeieSInsulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspartDiabetes Care2003263590596
   PubMed Web of Science ®Google Scholar
• RaslovaKTamerSCClausonPKarlDInsulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass indexClin Drug Invest2007274279285
   PubMed Web of Science ®Google Scholar
• DemssieYNYounisNSoranHThe role of insulin detemir in overweight type 2 diabetes managementVasc Health Risk Manag200953553560
   PubMedGoogle Scholar
• DaviesMKhuntiKInsulin management in overweight or obese type 2 diabetes patients: the role of insulin glargineDiabetes Obes Metab200810Suppl 2S42S49
   PubMedGoogle Scholar
• DaviesMJDerezinskiTPedersenCBClausonPReduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemiaDiabetes Technol Ther2008104273277
   PubMed Web of Science ®Google Scholar
• HermansenKDaviesMDoes insulin detemir have a role in reducing risk of insulin-associated weight gain?Diabetes Obes Metab200793209217
   PubMed Web of Science ®Google Scholar
• TschritterOHennigeAMPreisslHCerebrocortical beta activity in overweight humans responds to insulin detemirPLoS One2007211e1196
   PubMed Web of Science ®Google Scholar
• HallschmidMJauch-CharaKKornOEuglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effectsDiabetes2010112 [Epub ahead of print].
   Web of Science ®Google Scholar
• ŻełobowskaKGumprechtJGrzeszczakWMitogenic potency of insulin glarginePol J Endocrinol20096013439
   Google Scholar
• ZibIRaskinPNovel insulin analogues and its mitogenic potentialDiabetes Obes Metab200686611620
   PubMed Web of Science ®Google Scholar
• DejgaardALynggaardHRåstamJKrogsgaard ThomsenMNo evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysisDiabetologia200952122507251219838665
   PubMed Web of Science ®Google Scholar
• KurtzhalsPSchäfferLSorensenACorrelations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical useDiabetes2000496999100510866053
   PubMed Web of Science ®Google Scholar
• WadaTAzegamiMSugiyamaMTsunekiHSasaokaTCharacteristics of signaling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulinDiabetes Res Clin Pract2008813269277
   PubMed Web of Science ®Google Scholar
• ReynoldsLRComparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. CommentaryPostgrad Med20101221201203
   PubMed Web of Science ®Google Scholar